BioCentury | May 28, 2012
Emerging Company Profile

Delpor: Implantable antipsychotics

...success, they still have a limited therapeutic duration and poor pharmacokinetics, resulting in poor compliance. Delpor Inc....
...at a steady rate. Delpor's lead program is DLP-114, a Prozor device loaded with risperidone. Delpor...
...temperature. Nicolaou said Delpor has an undisclosed formulation technology that prevents the proteins from aggregating. Delpor's...
Items per page:
1 - 1 of 1
BioCentury | May 28, 2012
Emerging Company Profile

Delpor: Implantable antipsychotics

...success, they still have a limited therapeutic duration and poor pharmacokinetics, resulting in poor compliance. Delpor Inc....
...at a steady rate. Delpor's lead program is DLP-114, a Prozor device loaded with risperidone. Delpor...
...temperature. Nicolaou said Delpor has an undisclosed formulation technology that prevents the proteins from aggregating. Delpor's...
Items per page:
1 - 1 of 1